Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.
Soticlestat, a novel agent, did not significantly reduce convulsive seizure frequency in Dravet syndrome patients compared to placebo in the SKYLINE trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.